Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG)

Background: The combination of cisplatin (CDDP) and 5-fluorouracil (5-FU) c an be regarded as a reference regimen in squamous cell carcinoma of the hea d and neck (SCCHN). Raltitrexed (Tomudex) is a direct and specific thymidil ate synthase (TS) inhibitor, which has shown clinical activity against SCCH N in a previous phase I study, when combined with 5-FU and levo-folinic aci d (LFA). Preclinical data support the combination of CDDP and raltitrexed. The aim of the present study was to evaluate the combination of cisplatin, raltitrexed, LFA and 5-FU in a phase I-II study. Patients and methods: Patients with locally advanced or metastatic SCCHN we re treated with a combination of cisplatin at the starting dose of 40 mg/m( 2), followed by raltitrexed at the starting dose of 2.5 mg/m(2) on day 1; l evo-folinic acid at fixed dose of 250 mg/m(2), followed by 5-fluorouracil a t the starting dose of 750 mg/m(2) on day 2. Doses of the three cytotoxic a gents were alternately escalated up to dose-limiting toxicity (DLT). Treatm ent was recycled every two weeks and given up to a maximum of eight courses ; after chemotherapy, patients with locally advanced disease received a loc oregional treatment. Results: Forty-five patients were entered into the study. Six dose levels w ere tested. At CDDP 50 mg/m(2), raltitrexed 3 mg/m(2), 5-FU 900 mg/m(2), fo ur out of six patients showed DLT, which was in all cases grade 4 neutropen ia. Therefore, this dose level was defined as maximum tolerated dose (MTD). CDDP 60 mg/m(2), raltitrexed 2.5 mg/m(2), LFA 250 mg/m(2), 5-FU 900 mg/m(2 ) was the dose level recommended for phase II. CDDP, Raltitrexed and 5-FU m ean actually delivered dose intensities at the selected dose level were 26, 1.05, and 378 mg/m(2)/week, respectively. Neutropenia was the main side ef fect and was observed even at the lowest dose levels. Non-hematologic side effects were mild. Nine complete responses (20%) and twenty-one partial res ponses (47%) were observed, for an overall response rate of 67% (95% confid ence interval (95% CI): 51%-80%), according to intention to treat analysis. Fifteen of fifteen patients (100%) treated at the dose level selected for phase II had an objective response (5 complete responses, 10 partial respon ses). Conclusions: The results of our dose escalation clearly demonstrate that it is possible to combine CDDP, raltitrexed, and modulated 5-FU at effective doses, without unexpected toxicities. The response data point to an impress ive clinical activity, which will be better defined by an ongoing large pha se II study.